In his blood

[...]rather than adding another plant, starting in 2009, Biogen formed alliances with other biotechs that aren't direct competitors but had the capacity to make necessary molecules for the company, Ganguly told N.C. State University business-school students at a February lecture. The moves pann...

Full description

Saved in:
Bibliographic Details
Published inBusiness, North Carolina Vol. 35; no. 5; p. 14
Main Author Burritt, Chris
Format Trade Publication Article
LanguageEnglish
Published Charlotte Business-North Carolina 01.05.2015
Subjects
Biotechnology industry
Drugs
Ganguly, Joydeep
Manufacturing
Medical research
Multiple sclerosis
Pharmaceutical industry
Science
Students
North Carolina
United States > US
Online AccessGet full text

Cover

More Information
Summary:[...]rather than adding another plant, starting in 2009, Biogen formed alliances with other biotechs that aren't direct competitors but had the capacity to make necessary molecules for the company, Ganguly told N.C. State University business-school students at a February lecture. The moves panned out. Since 2010, annual revenue increased 134% to $8.2 billion last year, and the company's stock jumped from around $50 per share to as high as $475 in March.
ISSN:0279-4276